Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-06-02 Purchase |
2025-06-03 4:46 pm |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
10,000 | $1.0665 | $10,665 | 1,516,262 (Indirect Direct) |
View |
| 2025-05-28 Sale |
2025-05-30 5:40 pm |
AN2 Therapeutics Inc. | ANTX | Leonard Braden Michael 10% Owner |
2,532,000 | $1.1345 | $2,872,477 | 3,217,432 (Indirect) |
View |
| 2025-05-28 Purchase |
2025-05-29 4:17 pm |
AN2 Therapeutics Inc. | ANTX | FitzPatrick Margaret M Director |
8,610 | $1.1769 | $10,133 | 8,610 (Direct) |
View |
| 2025-01-03 Sale |
2025-01-07 8:02 pm |
AN2 Therapeutics Inc. | ANTX | Day Lucy Chief Financial Officer |
2,957 | $1.341 | $3,965 | 32,670 (Direct) |
View |
| 2025-01-03 Sale |
2025-01-07 8:00 pm |
AN2 Therapeutics Inc. | ANTX | Chanda Sanjay Chief Development Officer |
2,957 | $1.341 | $3,965 | 29,824 (Direct) |
View |
| 2025-01-03 Sale |
2025-01-07 7:57 pm |
AN2 Therapeutics Inc. | ANTX | Prior Stephen David Chief Strategy Officer |
2,029 | $1.341 | $2,721 | 33,313 (Direct) |
View |
| 2025-01-03 Sale |
2025-01-07 7:57 pm |
AN2 Therapeutics Inc. | ANTX | Eizen Joshua M See Remarks |
9,663 | $1.341 | $12,958 | 116,672 (Direct) |
View |
| 2024-12-06 Purchase |
2024-12-10 8:46 pm |
AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director |
60,000 | $1.4451 | $86,708 | 652,573 (Indirect) |
View |
| 2024-11-26 Purchase |
2024-11-27 7:07 pm |
AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director |
75,000 | $1.4091 | $105,685 | 622,573 (Indirect) |
View |
| 2024-11-27 Purchase |
2024-11-27 4:16 pm |
AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director |
2,000 | $1.4 | $2,800 | 531,079 (Indirect Direct) |
View |
| 2024-11-19 Purchase |
2024-11-21 6:00 pm |
AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director |
200,000 | $1.0656 | $213,128 | 514,788 (Indirect) |
View |
| 2024-11-18 Purchase |
2024-11-20 4:11 pm |
AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director |
25,000 | $1.0018 | $25,046 | 529,079 (Indirect Direct) |
View |
| 2024-11-18 Purchase |
2024-11-18 8:51 pm |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
50,000 | $0.9994 | $49,970 | 1,361,012 (Indirect Direct) |
View |
| 2024-08-14 Purchase |
2024-08-14 8:24 pm |
AN2 Therapeutics Inc. | ANTX | Leonard Braden Michael 10% Owner |
1,500,000 | $1.04 | $1,560,000 | 5,749,432 (Indirect) |
View |
| 2024-08-09 Sale |
2024-08-13 5:03 pm |
AN2 Therapeutics Inc. | ANTX | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. 10% Owner |
3,525,094 | $1.08 | $3,807,102 | 300,853 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-05-22 Option Award |
2025-05-23 5:04 pm |
N/A 2035-05-21 |
AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director |
19,111 | $0 | 19,111 (Direct) |
View |
| 2025-05-22 Option Award |
2025-05-23 5:03 pm |
N/A 2035-05-21 |
AN2 Therapeutics Inc. | ANTX | Martin Patricia A. Director |
19,111 | $0 | 19,111 (Direct) |
View |
| 2025-05-22 Option Award |
2025-05-23 4:59 pm |
N/A 2035-05-21 |
AN2 Therapeutics Inc. | ANTX | FitzPatrick Margaret M Director |
19,111 | $0 | 19,111 (Direct) |
View |
| 2025-05-22 Option Award |
2025-05-23 4:58 pm |
N/A 2035-05-21 |
AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director |
19,111 | $0 | 19,111 (Direct) |
View |
| 2025-05-22 Option Award |
2025-05-23 4:57 pm |
N/A 2035-05-21 |
AN2 Therapeutics Inc. | ANTX | Spigelman Melvin K Director |
19,111 | $0 | 19,111 (Direct) |
View |
| 2025-05-22 Option Award |
2025-05-23 4:56 pm |
N/A 2035-05-21 |
AN2 Therapeutics Inc. | ANTX | Wong Stephanie Director |
19,111 | $0 | 19,111 (Direct) |
View |
| 2025-05-22 Option Award |
2025-05-23 4:51 pm |
N/A 2035-05-21 |
AN2 Therapeutics Inc. | ANTX | Marks Gilbert Lynn Director |
19,111 | $0 | 19,111 (Direct) |
View |
| 2025-05-22 Option Award |
2025-05-23 4:51 pm |
N/A 2035-05-21 |
AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director |
19,111 | $0 | 19,111 (Direct) |
View |
| 2025-04-10 Option Award |
2025-04-11 5:08 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director |
10,523 | $0 | 551,418 (Direct) |
View |
| 2025-04-10 Option Award |
2025-04-11 5:03 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director |
9,705 | $0 | 2,392,177 (Direct) |
View |
| 2025-04-10 Option Award |
2025-04-11 4:57 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Martin Patricia A. Director |
3,065 | $0 | 6,231 (Direct) |
View |
| 2025-04-10 Option Award |
2025-04-11 4:55 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Marks Gilbert Lynn Director |
9,705 | $0 | 41,507 (Direct) |
View |
| 2025-02-26 Option Award |
2025-02-28 4:27 pm |
N/A 2035-02-25 |
AN2 Therapeutics Inc. | ANTX | Chanda Sanjay Chief Development Officer |
150,750 | $0 | 180,574 (Direct) |
View |
| 2025-02-26 Option Award |
2025-02-28 4:26 pm |
N/A 2035-02-25 |
AN2 Therapeutics Inc. | ANTX | Day Lucy Chief Financial Officer |
139,500 | $0 | 172,170 (Direct) |
View |
| 2025-02-26 Option Award |
2025-02-28 4:22 pm |
N/A 2035-02-25 |
AN2 Therapeutics Inc. | ANTX | Eizen Joshua M See Remarks |
175,500 | $0 | 292,172 (Direct) |
View |
| 2025-02-26 Option Award |
2025-02-28 4:22 pm |
N/A 2035-02-25 |
AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer |
435,750 | $0 | 1,796,762 (Direct) |
View |
| 2025-02-26 Option Award |
2025-02-28 4:19 pm |
N/A 2035-02-25 |
AN2 Therapeutics Inc. | ANTX | Prior Stephen David Chief Strategy Officer |
84,000 | $0 | 117,313 (Direct) |
View |
| 2024-12-19 Option Award |
2024-12-23 6:42 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Martin Patricia A. Director |
3,166 | $0 | 3,166 (Direct) |
View |
| 2024-12-19 Option Award |
2024-12-23 6:40 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director |
8,972 | $0 | 2,382,472 (Direct) |
View |
| 2024-12-19 Option Award |
2024-12-23 6:38 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Marks Gilbert Lynn Director |
8,972 | $0 | 31,802 (Direct) |
View |
| 2024-12-19 Option Award |
2024-12-23 6:33 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director |
9,816 | $0 | 540,895 (Direct) |
View |
| 2024-12-19 Option Award |
2024-12-23 6:32 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director |
9,077 | $0 | 1,243,938 (Direct) |
View |
| 2024-11-04 Option Award |
2024-11-05 4:57 pm |
N/A 2034-11-03 |
AN2 Therapeutics Inc. | ANTX | Prior Stephen David Chief Strategy Officer |
30,375 | $0 | 55,592 (Direct) |
View |
| 2024-11-04 Option Award |
2024-11-05 4:51 pm |
N/A 2034-11-03 |
AN2 Therapeutics Inc. | ANTX | Eizen Joshua M See Remarks |
94,500 | $0 | 189,335 (Direct) |
View |
Ownership |
2024-11-05 4:49 pm |
N/A N/A |
AN2 Therapeutics Inc. | ANTX | Prior Stephen David Chief Strategy Officer |
0 | $0 | 135,417 (Direct) |
View |